Alk

ALK, a pharmaceutical preparation manufacturing company headquartered in DK, reported a total of approximately 69.6 billion kg CO2e in emissions for 2023. This figure encompasses Scope 1, Scope 2, and Scope 3 emissions. Scope 1 emissions for 2023 were approximately 5.1 million kg CO2e, while Scope 2 emissions (market-based) were about 360,000 kg CO2e. Scope 3 emissions were the most significant, totalling approximately 64.1 million kg CO2e, with purchased goods and services being the largest contributor within this scope.

In 2022, ALK's total emissions were approximately 75.7 billion kg CO2e. Scope 1 emissions were around 4.9 million kg CO2e and Scope 2 emissions (market-based) were approximately 347,000 kg CO2e, with Scope 3 emissions at about 70.5 billion kg CO2e.

ALK has set ambitious climate commitments. Through Science Based Targets initiative (SBTi) validation, the company is committed to reducing absolute Scope 1 and 2 greenhouse gas emissions by 42.0% by 2030, using 2022 as a base year. This target is considered consistent with limiting warming to 1.5°C. Furthermore, ALK aims to have 80% of its suppliers, covering key categories like purchased goods and services and transportation, have science-based targets by 2028.

Prior to the SBTi targets, ALK reported achieving a 41% reduction in Scope 1 and Scope 2 emissions from a 2019 baseline by 2022. In 2021, total Scope 1 and 2 emissions (market-based) were approximately 8.6 million kg CO2e, and in 2020, they were approximately 8.5 million kg CO2e. For these earlier years, comprehensive Scope 3 data was not fully disclosed, with specific categories like purchased goods and services missing from the reporting.